Oxaliplatin 100 mg / 20 ml

Indonesia • Ferron Par Pharmaceuticals


Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for:

  • Adjuvant treatment of stage III (Duke’s C) colon cancer, after complete resection of primary tumor
  • Treatment of metastatic colorectal cancer


Oxaliplatin 100 mg


1 vial of 20 ml

Dosage Forms


ATC Classification



Consult Your Doctor
Safety of this item for use with alcohol has not been established. Please consult your doctor.
Not Recommended
This item should not be used while operating heavy machinery.
Not Recommended
This item is not safe for use during pregnancy.
Not Recommended
This item is not safe for use during lactation.


Up to 18 Years

Not recommended.

18 Years Old and Above

In adjuvant setting:
The recommended dose for oxaliplatin is 85 mg/m² intravenously, repeated every 2 weeks for 12 cycles (6 months).

In treatment of metastatic colorectal cancer:

The recommended dose for oxaliplatin is 85 mg/m² intravenously repeated every 2 weeks.

Dosage given should be adjusted according to tolerability (see “warnings and precautions”).

Oxaliplatin should always be administered before fluoropyrimidines. Oxaliplatin is administered as a 2-6 hours intravenous infusion in 250 to 500 ml of 5% dextrose infusion to give a concentration not less than 0.2 mg/ml.

Oxaliplatin was mainly used in combination with continuous infusion 5-fluorouracil based regimens. For the two-weekly treatment schedule 5-fluorouracil regimens combining bolus and continuous infusion were used. In the event of extravasation, administration must be discontinued immediately.

Patients with Severe Renal Impairment

Oxaliplatin must not be administered in patients with severe renal impairment.